Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II afatinib monotherapy in HER2-positive hormone-refractory prostate cancer
2010-024164-18Phase 2Terminated
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib in prostate cancer (PCa), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: PSA response rate. Started Mar 2011; status: terminated.
02
Drugs
afatinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2010-024164-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024164-18.